Cited by 807Cardiomyopathy and Myosin StudiesCardiovascular Effects of ExerciseViral Infections and Immunology Research

The DOI matches its Crossref record; 518 of the 518 references it cites were found in a registry or an index.

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Ommen, Steve R., Ho, Carolyn Y., Asif, Irfan M., Balaji, Seshadri, Burke, Michael A., Day, Sharlene M., Dearani, Joseph A., Epps, Kelly C., Evanovich, Lauren, Ferrari, Victor A., Joglar, José A., Khan, Sadiya S., Kim, Jeffrey J., Kittleson, Michelle M., Krittanawong, Chayakrit, Martinez, Matthew W., Mital, Seema, Naidu, Srihari S., Saberi, Sara, Semsarian, Christopher, Times, Sabrina, Waldman, Cynthia Burstein·2024·Circulation

DOI 10.1161/cir.0000000000001250

Open this paper in CoChat — free account

Abstract

AIM: The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy” provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy” have been updated with new evidence to guide clinicians.

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000001250

Cites

518 of 518 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2011 Compendium of Physical Activities: A Second Update of Codes and MET Values
AINSWORTH, B. E., HASKELL, W. L., HERRMANN, S. D., MECKES, N., BASSETT, D. R., TUDOR-LOCKE, C., GREER, J. L., VEZINA, J., WHITT-GLOVER, M. C., & LEON, A. S. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31821ece12 · Cited by 6,317
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
Cleland, J. G. F., Daubert, J., Erdmann, E., Freemantle, N., Gras, D., KAPPENBERGER, L. J., & Tavazzi, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050496 · Cited by 6,300
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Self-citation
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686

Show all 514 references

Research works printed but not linked: 227

Committee on Standards for Systematic Reviews of Comparative Effectiveness Research Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. National Academies Press; 2011.
Animal Studies-Standard-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/54.
Guidelines-Broad-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/75.
Guidelines-Standard-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/77.
RCT/ CCT-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/108.
SR/ MA/ HTA/ ITC-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022: Accessed September 14, 2022. https://searchfilters.cadth.ca/link/99.
10.1016/s0025-6196(11)64198-0 · DOI
10.1016/j.jacc.2014.05.003 · DOI · Paper page
10.1056/nejmra1710575 · DOI · Paper page
10.1161/circulationaha.117.033200 · DOI · Paper page
10.1001/jamacardio.2015.0354 · DOI · Paper page
10.1056/nejmra1710575 · DOI · Paper page
10.1016/j.jacc.2015.01.019 · DOI
10.1016/j.jacc.2014.05.003 · DOI · Paper page
10.1016/j.jacc.2018.10.007 · DOI
10.1016/j.echo.2010.10.006 · DOI
10.1161/circulationaha.106.644682 · DOI
10.1016/j.amjcard.2017.08.047 · DOI
10.1093/ehjci/jew313 · DOI
10.1016/j.jacc.2005.02.090 · DOI
10.1093/eurheartj/ehz396 · DOI
10.1016/j.jacc.2013.02.079 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1016/j.jacc.2016.01.071 · DOI
10.1016/j.jacc.2012.03.076 · DOI
10.1016/j.jacc.2010.11.002 · DOI
10.1016/j.echo.2011.03.006 · DOI
10.1161/circulationaha.107.698985 · DOI
10.1016/j.jcin.2011.02.014 · DOI
10.1016/j.amjcard.2007.09.111 · DOI
10.1161/01.cir.0000097110.55312.bf · DOI
10.1016/j.echo.2010.10.006 · DOI
10.1161/circulationaha.106.644682 · DOI
10.1016/j.amjcard.2017.08.047 · DOI
10.1093/ejechocard/jeq063 · DOI
10.1093/ehjci/jew313 · DOI
10.1136/hrt.2007.126003 · DOI
10.1056/nejmoa021332 · DOI · Paper page
10.1016/s0002-9149(99)80416-0 · DOI
10.1161/01.cir.0000162460.36735.71 · DOI
10.1016/j.jacc.2013.02.079 · DOI
10.1161/hcg.0000000000000054 · DOI
10.1093/eurheartj/ehq271 · DOI
10.1016/j.jacc.2012.02.068 · DOI
10.1161/circgen.117.001896 · DOI · Paper page
10.1161/circulationaha.114.013478 · DOI
10.1093/eurheartj/ehz396 · DOI
10.1161/circulationaha.117.033200 · DOI · Paper page
10.1016/j.hrthm.2011.07.017 · DOI
10.1161/circulationaha.111.090514 · DOI
10.1161/circgenetics.116.001620 · DOI
10.1161/circulationaha.118.038846 · DOI
10.1016/j.jacc.2015.01.019 · DOI
10.1161/circulationaha.111.090514 · DOI
10.1093/eurheartj/ehz396 · DOI
10.1161/circulationaha.118.037264 · DOI
10.1161/circulationaha.118.038846 · DOI
10.1016/j.jpeds.2017.03.033 · DOI
10.1093/eurheartj/ehr092 · DOI · Paper page
10.1148/radiol.2018180339 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1016/s0735-1097(03)00827-1 · DOI · Paper page
10.1161/circep.116.004604 · DOI
10.1007/s10554-016-0858-4 · DOI
10.1016/j.amjcard.2016.11.010 · DOI
10.1016/j.amjcard.2010.01.367 · DOI
10.1016/j.jcmg.2016.02.031 · DOI
10.1161/circulationaha.113.007094 · DOI · Paper page
10.1016/j.jacc.2018.05.060 · DOI
10.1136/heartjnl-2013-305471 · DOI
10.1016/j.echo.2011.03.002 · DOI
10.1016/j.jacc.2015.02.061 · DOI · Paper page
10.1161/circulationaha.120.047235 · DOI
10.1111/cge.13157 · DOI
10.1016/j.hrthm.2019.04.040 · DOI
10.1093/europace/euz118 · DOI
10.1161/circulationaha.122.062699 · DOI
10.1161/circulationaha.120.047235 · DOI
10.1001/jamacardio.2019.2861 · DOI
10.1001/jamacardio.2018.0789 · DOI
10.1016/j.hrthm.2019.04.040 · DOI
10.1093/europace/euz118 · DOI
10.1177/2047487317702519 · DOI
10.1161/circheartfailure.113.000414 · DOI
10.1016/j.amjcard.2013.12.034 · DOI
10.1111/chd.12286 · DOI
10.1093/eurjpc/zwab181 · DOI
10.1016/j.jacc.2015.03.552 · DOI
10.1111/cge.13157 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1016/j.jjcc.2014.02.011 · DOI
10.1007/s10554-016-0858-4 · DOI
10.1016/j.amjcard.2016.11.010 · DOI
10.1016/j.amjcard.2010.01.367 · DOI
10.1016/j.jcmg.2016.02.031 · DOI
10.1161/circulationaha.113.007094 · DOI · Paper page
10.1016/j.jacc.2018.05.060 · DOI
10.1001/jamacardio.2019.1391 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1136/heartjnl-2013-305471 · DOI
10.1016/j.jacc.2020.04.045 · DOI
10.1161/circulationaha.119.044366 · DOI · Paper page
10.1016/j.jacc.2015.02.061 · DOI · Paper page
10.1161/circulationaha.122.062699 · DOI
10.1016/s0735-1097(99)00056-x · DOI
10.1016/j.amjcard.2010.06.077 · DOI · Paper page
10.1056/nejm200006153422403 · DOI
10.1016/s0140-6736(00)04005-8 · DOI
10.1161/circulationaha.108.798314 · DOI · Paper page
10.1016/s0735-1097(03)00827-1 · DOI · Paper page
10.1161/circep.116.004604 · DOI
10.1017/s1047951105001824 · DOI
10.1038/nrcardio.2017.6 · DOI
10.1001/jamacardio.2019.1391 · DOI
10.1001/jama.298.4.405 · DOI
10.1016/j.ahj.2013.06.009 · DOI
10.1016/s0735-1097(99)00056-x · DOI
10.1161/circulationaha.108.798314 · DOI · Paper page
10.1016/j.amjcard.2010.06.077 · DOI · Paper page
10.1093/eurheartj/ehq308 · DOI
10.1056/nejm200006153422403 · DOI
10.1016/j.jacc.2004.12.067 · DOI
10.1016/s0140-6736(00)04005-8 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1016/j.jjcc.2014.02.011 · DOI
10.1016/s0735-1097(03)00827-1 · DOI · Paper page
10.1161/circep.116.004604 · DOI
10.1136/heartjnl-2013-305471 · DOI
10.1093/eurheartj/eht439 · DOI · Paper page
10.1016/j.jacc.2020.04.045 · DOI
10.1161/circulationaha.119.044366 · DOI · Paper page
10.1016/j.jacc.2013.01.037 · DOI
10.1177/2047487317702519 · DOI
10.1007/s00246-011-9967-y · DOI
10.1016/s0735-1097(98)00493-8 · DOI
10.1016/j.jacc.2015.03.552 · DOI
10.1007/s00246-013-0676-6 · DOI
10.1161/circulationaha.115.017633 · DOI
10.1161/circulationaha.120.047235 · DOI
10.1093/eurjpc/zwab181 · DOI
10.1161/circulationaha.113.007094 · DOI · Paper page
10.1016/j.jcmg.2016.02.031 · DOI
10.1016/j.jacc.2018.05.060 · DOI
10.1016/j.amjcard.2013.12.034 · DOI
10.1161/circulationaha.112.136085 · DOI · Paper page
10.1016/j.jacc.2015.02.061 · DOI · Paper page
10.1016/j.amjcard.2020.04.042 · DOI
10.1016/j.hrthm.2019.04.040 · DOI
10.1016/j.jacc.2009.03.051 · DOI
10.1016/j.jacc.2013.01.037 · DOI
10.1161/cir.0000000000001063 · DOI · Paper page
10.1161/cir.0000000000000628 · DOI · Paper page
10.1161/circulationaha.106.644682 · DOI
10.1016/j.jacc.2005.02.090 · DOI
10.1016/j.jacc.2015.06.1333 · DOI · Paper page
10.1161/circulationaha.106.644682 · DOI
10.1016/j.jacc.2005.02.090 · DOI
10.1016/j.amjcard.2013.01.340 · DOI
10.1016/j.jcmg.2013.08.010 · DOI
10.1001/jamacardio.2016.0252 · DOI
10.1016/j.jtcvs.2018.11.148 · DOI
10.1016/j.mayocp.2018.07.022 · DOI
10.1016/j.jacc.2016.07.735 · DOI · Paper page
10.1016/j.echo.2018.10.011 · DOI
10.1136/hrt.2007.118018 · DOI
10.1161/circulationaha.117.029267 · DOI · Paper page
10.1161/01.cir.0000162460.36735.71 · DOI
Liebregts, M, Vriesendorp, PA, Mahmoodi, BK, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol HF. 2015;3:896–905.
10.1536/ihj.27.701 · DOI
10.1161/circulationaha.117.033200 · DOI · Paper page
10.1161/01.cir.0000097110.55312.bf · DOI
10.1161/cir.0000000000001063 · DOI · Paper page
10.1161/circulationaha.105.583500 · DOI
10.1093/eurheartj/ehq136 · DOI
10.1161/circheartfailure.114.002248 · DOI · Paper page
10.1253/circj.cj-16-0432 · DOI
10.1016/j.amjcard.2017.12.044 · DOI
10.1016/s0140-6736(20)31792-x · DOI · Paper page
10.1016/j.jacc.2020.04.045 · DOI
10.1016/j.ejheart.2008.03.006 · DOI
Gu, M, Jin, H, Hua, W, et al. Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy. J Geriatr Cardiol. 2017;14:238–244.
10.1016/j.jacc.2017.11.040 · DOI
10.1093/europace/euw327 · DOI
Rowin, EJ, Mohanty, S, Madias, C, et al. Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol EP. 2019;5:131–133.
10.1136/heartjnl-2013-305471 · DOI
10.1161/circulationaha.119.044366 · DOI · Paper page
10.1161/circheartfailure.114.001843 · DOI · Paper page
10.1016/s2213-8587(14)70241-4 · DOI
10.1016/j.amjcard.2016.08.092 · DOI
10.1111/jce.12982 · DOI
10.1161/circulationaha.117.029267 · DOI · Paper page
10.1016/j.jacc.2005.01.012 · DOI · Paper page
10.1161/jaha.116.005152 · DOI
10.1016/j.amjcard.2003.10.025 · DOI
10.1016/j.amjcard.2017.12.044 · DOI
10.1161/circheartfailure.114.001435 · DOI
10.1161/circep.110.957290 · DOI

200 of 227 shown

Sorted by citations

Items 201–300 of 806

QRS duration, left bundle branch block morphology, and outcomes among patients who undergo septal myectomy
Song, C., Cui, J., Guo, X., Zheng, X., Nie, C., Lu, T., Yang, Q., Wang, S., & Huang, X. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.12.018 · Cited by 3
Large Language Models for Cardiac MRI Diagnosis Based on Standardized Text Descriptions
Zhang, H., Zhou, J., Zhang, C., Lu, G., Lu, Z., Wang, L., Wang, L., Gong, H., Zhao, L., & Ma, X. C. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70327 · Cited by 3
National experience of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: A long-term multicenter retrospective study
Shloido, E., Popov, K., Chernyshov, S., & Kashtanov, M. G. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.11.248 · Cited by 3
Status of cardiovascular magnetic resonance in clinical application and scientific research: a national survey in China
Zhang, H., Jiang, M., Yang, W., Zhou, D., Wang, Y., Zhu, L., Zhang, Q., Sirajuddin, A., Arai, A. E., Zhao, S., et al. (2025) · Journal of Cardiovascular Magnetic Resonance · doi:10.1016/j.jocmr.2025.101877 · Cited by 3
Myocarditis in Hypertrophic Cardiomyopathy: Incidence and Contribution to Disease Progression and Outcome
Lutokhina, Y. A., Seifatova, N. B., Chernova, P., Kireeva, N. V., Komarov, R. N., Николаевна, В. М., Пирожков, С. В., Yantikova, E. V., Мустафаевна, Б. Н., Tlisov, B. M., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm28234 · Cited by 3
The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy
Ravi, S. N., O’Shea, M., Baqal, O. J., Fatunde, O. A., Savic, J., Green, D. B., Karikalan, S. A., Ibrahim, A., Schwartz, L., Geske, J. B., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.030 · Cited by 3
Self-citation
Interplay of ST2 downregulation and inflammatory dysregulation in hypertrophic cardiomyopathy pathogenesis
Cao, X., Wang, H., Hu, Z., Ma, W., Ding, P., Sun, H., & Guo, X. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1511415 · Cited by 3
Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy
Zheng, N., Chen, Y., Fu, Y., Xue, F., Zhang, F., Lin, L., & Jiang, T. (2025) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70119 · Cited by 3
Non-genetic factors and their impact on severity of inherited cardiomyopathies: Tipping the balance
Sweeting, J., Stafford, F., Hespe, S., Butters, A., & Ingles, J. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.11.003 · Cited by 3
Genetic Profiling and Phenotype Spectrum in a Chinese Cohort of Pediatric Cardiomyopathy Patients
Xing, G., Chen, L., Lv, L., Xu, G., Duan, Y., Li, J., Li, X., & Wang, Q. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12120466 · Cited by 3
Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten
Kokori, E., Patel, R., Olatunji, G. D., Muili, A. O., Ajekiigbe, V. O., Moradeyo, A. A., Babalola, A. E., Kwape, J. M., Omoworare, O. T., & Aderinto, N. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102802 · Cited by 3
Comparison of intelligent virtual reality first‐aid training outcomes among individuals with different demographic characteristics
Pan, J., Liu, Y., Yang, C., Zeng, P., Gong, T., Tao, L., Zheng, Y., Ye, G., & Zhang, N. (2024) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.14135 · Cited by 3
Presence of Apical Aneurysm and Its Impact on Left Ventricular Mechanics and Mechano‐Energetic Coupling in Patients With Apical Hypertrophic Cardiomyopathy
Mihos, C. G., Guigui, S. A., Horvath, S. A., Venkataraman, P., Fernandez, R., & Elajami, T. K. (2024) · Echocardiography · doi:10.1111/echo.15938 · Cited by 3
Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.02.009 · Cited by 3
Associations between procedural volume, costs, and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy in US hospitals
Hernandez, E. J. M., Krishnaswami, S., Dubey, A., Singh, N., Jonkman, A. G., Cao, Z., Tyagi, M., Lipkin, C. B., & Wang, A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2468127 · Cited by 3
ALPK3 Heterozygous Truncating Variants Cause Late-Onset Hypertrophic Cardiomyopathy With Frequent Apical Involvement and Apical Aneurysm
Busse, L., Huth, E. A., Abraham, M. R., Abraham, T. P., Padmanabhan, A., Wojciak, J., Wright, G., Aatre, R., Campagna, R., Jackson, E., et al. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005186 · Cited by 3
In silico estimation of thrombogenic risk after left atrial appendage excision: Towards digital twins in atrial fibrillation
Albors, C., Terreros, N. A., Saiz-Vivó, M., Zappala, P., Terpstra, M. M., Olivares, A. L., Planken, R. N., van Boven, W. J., Driessen, A. H. G., de Groot, J. R., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110483 · Cited by 3
Subaortic membrane in adult patients: retrospective study of clinical characteristics, outcomes, and echocardiographic associations and review of literature
Itare, V. B., Javed, N., Rivas, R. P., Mandalapu, N., Mehta, A., Ali, N., Ashraf, S., Molina, M., & Nicu, M. (2025) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-025-03489-5 · Cited by 3
T1 Mapping and Interstitial Fibrosis as a Marker for Heart Failure in Hypertrophic Cardiomyopathy
Rahman, S. U., & Rowin, E. J. (2025) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017938 · Cited by 3
Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data
Patel, N., Gaonkar, M., Pampana, A., Shetty, N. S., Vekariya, N., Li, P., Arora, G., & Arora, P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.01.003 · Cited by 2
Reslice3Dto2D: Introduction of a software tool to reformat 3D volumes into reference 2D slices in cardiovascular magnetic resonance imaging
Viezzer, D., Fenski, M., Grandy, T. H., Kuhnt, J., Hadler, T., Lange, S., & Schulz‐Menger, J. (2024) · BMC Research Notes · doi:10.1186/s13104-024-06931-4 · Cited by 2
Discrimination of Left Atrial Strain Patterns in Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: a Cardiac Magnetic Resonance Feature
Xu, H., Deng, W., Pan, Z., Yao, K., Yang, J., Wang, Z., Gao, H., Shu, H., Zhao, R., Yu, Y., et al. (2024) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-024-01293-6 · Cited by 2
Comparison of cardiac morphological and functional changes according to magnetic resonance imaging with the genetic testing data in patients with hypertrophic cardiomyopathy
Gagarina, E. V., Mershina, E. A., Сергеевна, Ч. О., Myasnikov, R. P., Kulikova, O. V., Kudryavtseva, M. M., & Sinitsyn, V. E. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6113 · Cited by 2
Echocardiographic Updates in the Assessment of Cardiomyopathy
Liu, B., Suthar, K., & Gerula, C. M. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02159-7 · Cited by 2
Cardiac myosin inhibition in hypertrophic cardiomyopathy: review of the evolving evidence base
Desai, M. Y., & Bonow, R. O. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2497847 · Cited by 2
Efficacy of mavacamten in patients with hypertrophic cardiomyopathy and mid-ventricular obstruction: case series
Rella, V., Muraru, D., & Crotti, L. (2025) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaf229 · Cited by 2
Contemporary practice and resource availability for genetic testing in paediatric hypertrophic cardiomyopathy
Sandmann, C., Klaassen, S., Kaski, J. P., & Norrish, G. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2025-110696 · Cited by 2
A Narrative Review of Current and Investigational Therapies in Hypertrophic Cardiomyopathy
Ogurek, I., Gill, R. S., Tasouli-Drakou, V., Joseph, R., Khalid, A., Houshmand, N., & Tak, T. (2025) · Biomedicines · doi:10.3390/biomedicines13061327 · Cited by 2
Aficamten in the treatment of obstructive hypertrophic cardiomyopathy
Saleh, D., Eskandari, M., & Choudhury, L. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2521183 · Cited by 2
Utility of Transesophageal Echocardiography and Isoproterenol Provocation in Detecting Latent Obstruction in Hypertrophic Cardiomyopathy
Nazif, K., Bavishi, A. A., & Martinez, M. W. (2025) · CJC Open · doi:10.1016/j.cjco.2025.06.015 · Cited by 2
Self-citation
Sailing Across Contraception, Pregnancy, and Breastfeeding: The Complex Journey of Women with Cardiomyopathies
Carella, M. C., Santobuono, V. E., Grosso, F. M., Dicorato, M. M., Basile, P., Dentamaro, I., Naccarati, M. L., Santoro, D., Monitillo, F., Valecce, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144977 · Cited by 2
Chemical myectomy with mavacamten in patients with obstructive hypertrophic cardiomyopathy with prior septal reduction therapy: A single-center experience
Hundal, P., Abood, Z., Sanders, H. R., Misicka, A., Galazka, P. Z., Jahangir, A., Jan, M. F., & Tajik, A. J. (2025) · JTCVS Open · doi:10.1016/j.xjon.2025.07.007 · Cited by 2
Effects of Alcohol Septal Ablation on Exercise Hemodynamics, Symptoms, and Quality of Life in Obstructive Hypertrophic Cardiomyopathy
Dybro, A. M., Rasmussen, T. B., Nielsen, R. R., Ladefoged, B. T., Pedersen, A. L. D., Terkelsen, C. J., Andersen, M. J., Jensen, M. K., & Poulsen, S. H. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.041328 · Cited by 2
Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation
Stendahl, J. C., Sen, S., Butzner, M., Papademetriou, E., Potluri, R. C., Liu, X., Jacoby, D. L., & Freeman, J. V. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038755 · Cited by 2
Genetic, Clinical, and Sociodemographic Profile of Individuals with Diagnosis or Family History of Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort
Santos, E. D. S., Kuhn, G. D. C., de Almeida, A. P., Pimentel, J. V. A., Neto, N. V. F., Melo, B. C., de Oliveira, D. P., Gonçalves, L. F., Aragão, A. B. L., Ferreira, C. F. B. D. M., et al. (2025) · Genes · doi:10.3390/genes16091100 · Cited by 2
Challenges in Interpretation and Reporting of Gross, Histologic, and Genetic Autopsy Findings
Mazo, Y., Pagani, A., Hellwig, L. D., Gordon, C. J., Vinson, A., Schopp, E. M., Hughes, B. N., Schacht, J. P., Hughes, J. J., Castro, M. J. D., et al. (2025) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000001070 · Cited by 2
Endothelial Cell‐Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy
Tamura, S., Akita, K., Fifer, M. A., Tower-Rader, A. F., Maurer, M. S., & Shimada, Y. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042887 · Cited by 2
Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers
Ajufo, E. C., Kany, S., Jurgens, S. J., Churchill, T. W., Guseh, J. S., Aragam, K. G., Nauffal, V., Pirruccello, J. P., Choi, S. H., Lakdawala, N. K., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4466 · Cited by 2
Self-citation
A Review of Multimodality Imaging in Hypertrophic Cardiomyopathy: Diagnosis, Risk Stratification, and Therapeutic Guidance
Gandhi, R., Ooi, E. L., Mugwagwa, A. N., Botrous, C., & Raman, B. (2025) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.240555 · Cited by 2
Medicolegal implications and litigation trends in the diagnosis and management of cardiomyopathies in the United States
Weller, S. L., Costa, A., Suits, A., Zia, A., Petek, B. J., & Masri, A. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.11.006 · Cited by 2
AI Applications in Electrocardiography for Ischemic and Structural Heart Disease: A Review of the Current State
Kim, E. J., Gala, D., Ayyad, M., Pramanik, M., & Makaryus, A. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010316 · Cited by 2
Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China
Yang, W., Shi, H., Chang, S., Zhang, Y., Jixiang, A., Wu, C., Qian, J., Ge, J., & Zhang, S. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/5690104 · Cited by 2
Promises and challenges of AI-enabled methods for myocardial characterisation in cardiovascular magnetic resonance
McWilliams, N., Varela, M., & Joy, G. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1638861 · Cited by 2
Evaluation and management of chest pain from cardiovascular causes in female patients
Diercks, D., Cao, M., McHugh, M. C., Kibbey, C., & Farooqi, S. (2026) · BMJ · doi:10.1136/bmj-2025-086177 · Cited by 2
Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials
Fahim, M., Eldawud, D., Wahadneh, O., Wang, R. X., Gorantla, A., Sharma, N., Khouri, P., & Salciccioli, L. F. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.018 · Cited by 2
Integrating ECG Into the Mayo Score Enhances Genotype Prediction in Hypertrophic Cardiomyopathy
Hiruma, T., Inoue, S., Dai, Z., Nomura, S., Kubo, T., Sugiura, K., Izumi, Y., Morisaki, H., Suzuki, A., Kashimura, T., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044501 · Cited by 2
SGLT-2 inhibitors improve cardiac function in hypertrophic cardiomyopathy: a real-world propensity score-matched study
Ding, C., Lv, F., Wang, L., & Xu, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1742682 · Cited by 2
Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document
Martens, P., Olivotto, I., García‐Pavía, P., Michels, M., Desai, M. Y., & Müllens, W. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag035 · Cited by 2
Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers
Grupper, A., Sverdlov, A. L., Cheema, B. S., Nasrollahizadeh, A., & Hosseini, K. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10603-9 · Cited by 2
Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction
Yang, L., Dai, H., & rong, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1807582 · Cited by 2
Atrial fibrillation recurrence and outcomes in patients with hypertrophic cardiomyopathy: Insights from a nationwide real-world cohort
Aglan, A., Fath, A. R., Silver, J. S., Harnish, P. R., Hook, B. G., Maron, M., & Rowin, E. J. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.03.1906 · Cited by 2
Long-Term Impact of Frailty on Outcomes Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy
Jain, H., Patel, N., Jain, J., Ahmed, M., Goyal, A., Passey, S., Baqal, O. J., Salerno, C., Alsidawi, S., Kapadia, S., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102767 · Cited by 2
Self-citation
Multimodality Imaging in Hypertrophic Cardiomyopathy
Escribano, D., Díaz-Peláez, E., & Delgado, V. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.14 · Cited by 2
High-sensitivity cardiac troponin I for enhanced risk stratification in primary prevention for sudden cardiac death in hypertrophic cardiomyopathy
Lai, Z., Li, X., Fan, S., Yan, H., Zhu, H., He, C., Yao, Y., & Fan, X. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.05.010 · Cited by 2
Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores
Costantino, J., Ballatore, F., Porcelli, D., Romani, B., Campoli, M., Zuccaro, L. M., Marchionni, G., Alfarano, M., Costantino, S., & Chimenti, C. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060287 · Cited by 2
Machine Learning–based Model for Major Adverse Cardiac Event Prediction in Patients with Hypertrophic Cardiomyopathy
Geyer, T., McIntosh, C., Sood, V., de Matos, J. F. R. G., McKee, H., & Hanneman, K. A. (2026) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.250433 · Cited by 2
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM
Maron, M. S., Masri, A., Bhatia, A., Peña‐Peña, M. L., Sherrid, M. V., Figueiredo, E. L., Arad, M., Choudhury, L., Claggett, B. L., COATS, C. J., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.082026 · Cited by 2
Self-citation
Transcatheter Myotomy for Hypertrophic Obstructive Cardiomyopathy
Danek, B. A., Elison, D. M., Chung, C. J., & McCabe, J. M. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02145-z · Cited by 2
Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials
Felix, N. S., Teixeira, L., Nogueira, A., Godoi, A., Costa, T. A., Pirez, J., Kherallah, R. Y., Serpa, F., Alexandre, F. K. B., de Farias, M. D. C. A. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00710-z · Cited by 2
Clinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy with indications for implantable cardioverter-defibrillator
Davydova, V. G., Gudkova, A. Y., Крутиков, А. Н., Полякова, А. А., & Kostareva, A. A. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5994 · Cited by 2
Effects of genetic mutations on left ventricular myocardial mechanics and fibrosis patterns in hypertrophic cardiomyopathy
Kim, M., Kim, Y., Chung, H., Seo, J.-W., Park, C. H., Kim, T., Rim, S., Lee, K., & Choi, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-85201-0 · Cited by 2
Value of Advanced Cardiac CTA in Clinical Assessment of Hypertrophic Cardiomyopathy: A Literature Review and Practical Implications
Touma, R. N., Pareddy, A. R., & Abidov, A. A. (2025) · Echocardiography · doi:10.1111/echo.70111 · Cited by 2
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy
Ostrominski, J. W., Claggett, B. L., Jerosch‐Herold, M., Raja, A. A., Day, S. M., Russell, M. W. W., Zahka, K. G., Pereira, A. C., Colan, S. D., Murphy, A. M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2024.5677 · Cited by 2
Self-citation
Cardiac Magnetic Resonance Imaging and Coronary Computed Tomography Angiography in Cardiomyopathy: Diagnostic and Prognostic Insights
Hanfi, Y. (2025) · Echocardiography · doi:10.1111/echo.70140 · Cited by 2
Clinical Characteristics and Prognosis of Patients with End-Stage Hypertrophic Cardiomyopathy from a Tertiary Center Cohort: Systolic Dysfunction and Advanced Diastolic Dysfunction
Afana, A. S., Adam, R. D., Militaru, S., Onciul, S., Andrei, O., Chiriță-Emandi, A., Puiu, M., Militaru, C., & Jurcut, R. O. (2025) · Diagnostics · doi:10.3390/diagnostics15091134 · Cited by 2
Effect of obesity on myocardial tissue characteristics in patients with hypertrophic cardiomyopathy: a cardiovascular magnetic resonance-based study
Wang, J., Pu, L., Zhang, J., Xu, R., Li, Y., Yu, M., Li, Y., Guo, J., Xu, Y., Kang, Y., et al. (2025) · Journal of Cardiovascular Magnetic Resonance · doi:10.1016/j.jocmr.2025.101903 · Cited by 2
Clinical and Echocardiographic Particularities of Hypertrophic Cardiomyopathy in a Brazilian Population and its Prognostic Impact
Luzuriaga, G. D. C. J., Arteaga-Fernández, E., Hotta, V. T., Ianni, B. M., Nastari, L., Ramires, F. J. A., da Fonseca, G. W. P., Mady, C., Fernandes, F., & Cardoso, J. N. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240640i · Cited by 2
Mass Spectrometric ITEM-FOUR Analysis Reveals Coding Single-Nucleotide Polymorphisms in Human Cardiac Troponin T That Evade Detection by Sandwich ELISAs Which Use Monoclonal Antibodies M7 and M11.7 from the Elecsys Troponin T® Assay
Kormann, K., Ruß, M., Röwer, C., Koy, C., & Glocker, M. O. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104892 · Cited by 2
Prognostic Value of Nonsustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy in a Brazilian Cohort: Comparison with World Literature
Silva, D. A., Arteaga-Fernández, E., Hotta, V. T., Mady, C., Ianni, B. M., Ramires, F. J. A., Nastari, L., Fernandes, F., & Cardoso, J. N. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240399i · Cited by 2
Whole-exome sequencing identifies novel truncating ALPK3 variants in a compound heterozygous state associated with pediatric hypertrophic cardiomyopathy and phenotypic heterogeneity
Wang, Y., Wang, Z., Sun, N., Yin, J., Chen, Y., Wang, C., & Yang, S. (2025) · Gene · doi:10.1016/j.gene.2025.149597 · Cited by 2
Myosin-ATPase inhibitor in real-world patients with obstructive HCM: a report by the Cardiomyopathies and Pericardial Diseases WG of the Italian Society of Cardiology
GREGORIO, C. D., Bellocchi, P., Napoli, A. M., Musumeci, B., Sammartino, A., Tini, G., Todiere, G., Barison, A., Chubuchnyi, V., Crotti, L., et al. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001746 · Cited by 2
Glycemic Influences on Hypertrophic Cardiomyopathy Myocardium: Insights From Cardiac MRI Feature Tracking
Peng, X., Huo, H., Gao, J., Jiang, X., & Yuan, Y. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70031 · Cited by 2
Transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy
Yan, C., Cao, Y., Song, S., Wang, Z., Liu, X., & Fan, T. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101742 · Cited by 2
Cardiac dissection techniques for pathoanatomical research on myocardial hypertrophy and anatomical teaching
Federspiel, J. M., Schmidt, P. H., Corvest, E., Hohneck, J., & Meier, C. (2025) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2025.152711 · Cited by 2
Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy
Choi, Y.-J., & Lakdawala, N. K. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00057-2 · Cited by 2
Myocardial Fibrosis Evaluated by T1 Mapping and Its Relationship to Left Ventricular Hypertrophy, Strain, and T2 Value in Hypertrophic Cardiomyopathy Without Late Gadolinium Enhancement
Yang, Z., Zhang, T.-Y., Gui, F.-D., Wen, M., Gao, L.-C., Long, Y.-T., Yi, Y., Bing, F., & Pan, S.-Y. (2025) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000862 · Cited by 2
Myocardial fibrosis predicts sudden cardiac death in patients with hypertrophic cardiomyopathy after cardiac electronic device implantation: Insights from cardiovascular magnetic resonance imaging
Fu, B., Lian, X., Huang, H., Long, T., Yang, J., Jiang, Y., Ning, X., Chen, X., Niu, H., Lu, M., et al. (2025) · Heart Rhythm O2 · doi:10.1016/j.hroo.2025.10.012 · Cited by 2
Modern Perspectives on Hypertrophic Cardiomyopathy—No One Size Fits All
Doliner, B., Gaddar, H., Kalil, R. K., & Postalian, A. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-24-8423 · Cited by 2
Centennial Collection: Hypertrophic Cardiomyopathy
Day, S. M. (2024) · Circulation · doi:10.1161/circulationaha.124.070134 · Cited by 2
Self-citation
Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions
Ambardekar, A. V. (2025) · New England Journal of Medicine · doi:10.1056/nejme2512100 · Cited by 2
Beyond coronary artery anatomy: Myocardial characterization by photon-counting detector CT in hypertrophic cardiomyopathy
Cadour, F., Mergen, V., & Soulat, G. (2025) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2025.10.001 · Cited by 2
Hypertrophic Cardiomyopathy Requiring Myectomy in a Young Patient With Systemic Lupus Erythematosus: A Case Report
Abdelmottaleb, W., Brown, D., Özbay, M. B., Rubinstein, D., & Thachil, R. (2024) · Cureus · doi:10.7759/cureus.61976 · Cited by 1
Initiale Diagnostik und Therapie des Schocks
Rießen, R., Bulla, P., Mengel, A., & Kumle, B. (2024) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-024-01195-z · Cited by 1
The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review
Othman, L., Koskina, L. E., Huerta, N. H., & Rao, S. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10476-w · Cited by 1
Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy With Midventricular Obstruction and Papillary Muscle Abnormalities
Sato, R., Satoh, T., Iguchi, K., Suwa, K., & Maekawa, Y. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2024.103183 · Cited by 1
Navigating Ventricular Fibrillation in the Setting of Hypertrophy Cardiomyopathy and Commotio Cordis
GONZALEZ, A., Ukenenye, E. U., Unal, S., & Joseph, J. (2025) · Cureus · doi:10.7759/cureus.79419 · Cited by 1
Artificial Intelligence-Based Electrocardiographic Analysis Facilitated Diagnosis of Hypertrophic Cardiomyopathy With Successful Treatment Using Mavacamten
Desai, M. Y., Rutkowski, K., & Ospina, S. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2024.103228 · Cited by 1
Hypertrophic cardiomyopathy overview: Genetics, screening, and treatment
Smania, M. A. (2025) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001109 · Cited by 1
Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy
Wang, H. C., Li, J., Hsi, D. H., Li, W., Ta, S., Jiao, Y., Shan, B., Chang, L., Ou, X., Lu, Y., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-325334 · Cited by 1
A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin
Pugsley, M. K., Hwee, D. T., Winters, B. R., Wang, J., Chin, E. R., Morgan, B. P., & Malik, F. I. (2025) · International Journal of Toxicology · doi:10.1177/10915818251326466 · Cited by 1
Associations of sex on economic burden in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from medical and pharmacy claims data
Butzner, M., Amonkar, S., Chen, M., Papademetriou, E., Potluri, R. C., Liu, X., & Abraham, T. P. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1463439 · Cited by 1
O Complexo Quebra-Cabeça do Fenótipo Hipertrófico: Uma Abordagem Prática para o Clínico
Félix, A. D. S., Barberato, S. H., de Melo, M. D. T., Rosa, S. A., & Cardim, N. M. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240529 · Cited by 1
Outcomes of Surgical Myectomy and Mitral Valve Repair for Hypertrophic Cardiomyopathy With vs Without Marked Septal Hypertrophy
Rahmouni, K., Issa, H. M. N., Toubar, O., Crean, A. M., Williams, A., Nguyen, H. D., Ponnambalam, M., Grau, J. B., Dickie, S., Maharajh, G., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.04.007 · Cited by 1
Prediction of sudden death in obstructive hypertrophic cardiomyopathy after septal myectomy: Targeting the candidate
Lu, T., Lu, Z., Meng, Y., Yang, Q., Cui, H. Z., Zhao, S., Song, Y., Zhu, C., & Wang, S. (2025) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.04.008 · Cited by 1
Cardiac Magnetic Resonance-Derived Left Ventricular Mechanical Dispersion Improves Risk Stratification of Hypertrophic Cardiomyopathy and its Correlations with Scar Heterogeneity
Zhao, X., Song, Y., Wang, L., Wang, L., Zhao, X., & Wang, J. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10631-0 · Cited by 1
Genetic landscape of hereditary cardiomyopathies and arrhythmias in China
Yang, L., Wang, Z., Zhang, S., Liu, Y., Jin, Y., Tian, Z., & Zhang, S. (2025) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2025.07.003 · Cited by 1
Enhancement of the Mayo Clinic HCM Genotype Predictor Score with Addition of Cardiac Magnetic Resonance Imaging
Félix, I. F., Vizentin, V. K., Aguirre, M. A., Patel, M. H., Geske, J. B., Araoz, P. A., Giudicessi, J. R., Ommen, S. R., Arruda-Olson, A. M., Ackerman, M. J., et al. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10667-2 · Cited by 1
Self-citation
Cardiac Hypertrophy: A Comprehensive Review from Prenatal Life to Young Adulthood
Avesani, M., Pomiato, E., Moscatelli, S., Sabatino, J., Borrelli, N., Luedke, L., Sarro, R. D., Pavesi, S., Pelaia, G., Mastellone, C., et al. (2025) · Children · doi:10.3390/children12080989 · Cited by 1
An Unusual Presentation of Third-Degree Atrioventricular Block in a Patient With Hypertrophic Cardiomyopathy
Gbee, E., Ssebuliba, M. K., & Nakagaayi, D. (2025) · Cureus · doi:10.7759/cureus.89041 · Cited by 1
Relationship between genotype and clinical phenotype of hypertrophic cardiomyopathy
Zhang, L., Wang, B., Wang, J., Zhao, J. W., & Liu, L. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107847 · Cited by 1

Authors: Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., Joglar, J. A., Khan, S. S., Kim, J. J., Kittleson, M. M., Krittanawong, C., Martinez, M. W., Mital, S., Naidu, S. S., Saberi, S., Semsarian, C., Times, S., & Waldman, C. B.
Affiliations: American Medical Society for Sports Medicine (US)
HRS representative.
Lay stakeholder representative.
AHA/ACC Joint Committee on Clinical Practice Guidelines liaison.
American Hospital Association (US)
PACES representative.
Joint ACC/AHA staff representative.
ORCID: Ommen, Steve R.
Ho, Carolyn Y.
Asif, Irfan M.
Balaji, Seshadri
Burke, Michael A.
Day, Sharlene M.
Dearani, Joseph A.
Ferrari, Victor A.
Joglar, José A.
Khan, Sadiya S.
Kim, Jeffrey J.
Kittleson, Michelle M.
Krittanawong, Chayakrit
Martinez, Matthew W.
Mital, Seema
Naidu, Srihari S.
Saberi, Sara
Semsarian, Christopher
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2024-06-04
Volume: 149
Issue: 23
Pages: e1239-e1311
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/cir.0000000000001250
OpenAlex: W4396750647
Cited by: 807
References: 514
Citations by year: 2026: 353 · 2025: 372 · 2024: 82
FWCI: 226.55
Type: journal article
Language: en
Update notices: correction (2024-08-19)
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Keywords: hypertrophic cardiomyopathy, disease management, inherited heart disease, diagnosis, treatment guidelines, American Heart Association, American College of Cardiology, American Society of Echocardiography
MeSH terms: American Heart Association, Cardiology, Cardiomyopathy, Hypertrophic, Humans, United States, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks